SEC Form 4 · accession 0001385508-19-000004
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phil Skolnick
Officer — Chief Scientific Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2019 | M | 10,000 | $9.00 | A | 10,000 | D | |
| Common StockF3 | Jan 2, 2019 | S | 7,768 | $13.84 | D | 2,232 | D | |
| Common StockF4 | Jan 4, 2019 | S | 2,232 | $13.48 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $9.00 | Jan 2, 2019 | M | 10,000 | D | Aug 6, 2018 | Feb 6, 2027 | Common Stock | 10,000 | 160,000 | D |
| Stock Option (right to buy)F5 | $13.61 | Jan 3, 2019 | A | 13,200 | A | — | Jan 2, 2029 | Common Stock | 13,200 | 13,200 | D |
Explanation of responses
- F1The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- F2The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- F3This transaction was executed in multiple trades at prices ranging from $13.61 to $14.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $13.47 to $13.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5On January 3, 2019, the reporting person was granted an option to purchase 13,200 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth anniversary of the Grant Date.